Overview Financials News + Filings Key Docs Charts Ownership
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Intellipharmaceutics International Inc. (IPCI)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/06/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 10/06/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:|
Docs:
|
"FORM 6-K",
"Intellipharmaceutics Reports Director Election Results Toronto, Ontario, September 14, 2023, Intellipharmaceutics International Inc. , a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, reports, as required by TSX rules, that the five nominees, each of whom was an incumbent director of the Company, identified in the Management Information Circular dated August 1, 2023 were elected as directors of the Company at the annual meeting of shareholders of the Company held today . The voting results, as set out in the scrutineer’s report for the Meeting, were as follows: Name of Nominee Votes For Votes Withheld Dr. Isa Odidi 3,825,956 9,248 99.8 % 0.24 % Dr. Amina Odidi 3,825,969 9...",
"Report on Voting Results" |
|
| 09/26/2023 |
6-K
| Quarterly results |
| 09/26/2023 |
6-K
| Quarterly results |
| 02/14/2023 |
SC 13G/A
| ARMISTICE CAPITAL, LLC reports a 10% stake in INTELLIPHARMACEUTICS INTERNATIONAL INC. |
| 10/14/2022 |
6-K
| Quarterly results|
Docs:
|
"FORM 6-K",
"Management Discussion And Analysis Of Financial Condition And Results Of Operations for the Three and nine Months Ended August 31, 2022",
"Condensed Unaudited Interim Consolidated Financial Statements and Notes to Condensed Unaudited Interim Consolidated Financial Statements of Intellipharmaceutics International Inc. for the Three and nine Months Ended August 31, 2022",
"Intellipharmaceutics Announces Third Quarter 2022 Results Toronto, Ontario October 14, 2022 – Intellipharmaceutics International Inc. , a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three and nine months ended August 31, 2022. All dollar amounts referenced herein are in United States dollars unless otherwise noted. · In August 2022 the Company announced that it has entered into a license and supply agreement with Taro Pharmaceuticals Inc. , by which the Company has granted Taro an exclusive license to market, sell and distribute in Canada, Desvenlafaxine Extended-release Tablets in the 50 mg and 100 mg strengths approved...",
"Form 52-109F2 - Chief Executive Officer",
"Form 52-109F2 - Chief Financial Officer" |
|
| 07/21/2022 |
6-K
| Quarterly results |
| 07/15/2022 |
6-K
| Quarterly results |
| 05/27/2022 |
6-K
| Quarterly results |
| 05/06/2022 |
20-F/A
| Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend] |
| 04/29/2022 |
6-K
| Quarterly results |
| 04/14/2022 |
6-K
| Quarterly results|
Docs:
|
"FORM 6-K",
"Management Discussion And Analysis Of Financial Condition And Results Of Operations for the Three Months Ended February 28, 2022",
"Condensed Unaudited Interim Consolidated Financial Statements and Notes to Condensed Unaudited Interim Consolidated Financial Statements of Intellipharmaceutics International Inc. for the Three Months Ended February 28, 2022",
"Intellipharmaceutics Announces First Quarter 2022 Results Toronto, Ontario April 14, 2022 – Intellipharmaceutics International Inc. , a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three months ended February 28, 2022. All dollar amounts referenced herein are in United States dollars unless otherwise noted. · In February 2022 the Company received marketing approval for the Canadian market from Health Canada for generic Pristiq in the 50 and 100 mg strengths. · In November 2021 the Company received final FDA approval for its Dexmethylphenidate Extended-release Capsules in the 5 mg, 10 mg, 30 mg and 40 mg strengths. The 15 ...",
"Form 52-109F2 - Chief Executive Officer",
"Form 52-109F2 - Chief Financial Officer" |
|
| 04/01/2022 |
20-F
| Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: |
| 03/01/2022 |
6-K
| Quarterly results |
| 02/28/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 02/14/2022 |
SC 13G/A
| ARMISTICE CAPITAL, LLC reports a 10% stake in Intellipharmaceutics International Inc. |
| 02/04/2022 |
6-K
| Quarterly results |
| 01/13/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:|
Docs:
|
"PRIMARY DOCUMENT",
"Intellipharmaceutics Mourns the Death of Valued Board Member Kenneth Eugene Keirstead Toronto, Ontario, January 13, 2022, Intellipharmaceutics International Inc. , a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, announced today with great sadness that Kenneth Keirstead, a member of the Company’s Board of Directors, has passed away. “We are all deeply saddened by Ken’s passing,” said Isa Odidi, CEO of Intellipharmaceuitcs. “Ken was a steadfast and highly valued member of our board who was known for his insights as both an entrepreneur and a scientist. Most of all, Ken was a dear member of the Intellipharmaceutics family and will be missed by all. ..." |
|
| 01/06/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 10/15/2021 |
6-K
| Quarterly results|
Docs:
|
"FORM 6-K",
"Management Discussion And Analysis Of Financial Condition And Results Of Operations for the Three and Nine Months Ended August 31, 2021",
"Condensed Unaudited Interim Consolidated Financial Statements and Notes to Condensed Unaudited Interim Consolidated Financial Statements of Intellipharmaceutics International Inc. for the Three and Nine Months Ended August 31, 2021",
"Intellipharmaceutics Announces Third Quarter 2021 Results Toronto, Ontario July 15, 2021 – Intellipharmaceutics International Inc. , a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three and nine months ended August 31, 2021. All dollar amounts referenced herein are in United States dollars unless otherwise noted. ● Effective May 5, 2021 our exclusive license agreements with Tris Pharma, Inc. for generic Seroquel XR®, generic Pristiq® and generic Effexor XR® were mutually terminated. Products were never supplied nor distributed under the licenses. Termination of the exclusive agreements may provide op...",
"Form 52-109F2 - Chief Executive Officer",
"Form 52-109F2 - Chief Financial Officer" |
|
| 07/15/2021 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 04/22/2021 |
6-K
| Quarterly results |
| 04/14/2021 |
6-K
| Quarterly results |
| 03/31/2021 |
20-F
| Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: |
| 03/01/2021 |
6-K
| Quarterly results |
| 03/01/2021 |
6-K
| Quarterly results |
| 02/16/2021 |
SC 13G
| ARMISTICE CAPITAL, LLC reports a 10% stake in Intellipharmaceutics International Inc. |
| 12/23/2020 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:|
Docs:
|
"PRIMARY DOCUMENT",
"Intellipharmaceutics Reports Director Election Results Toronto, Ontario, December 23, 2020, Intellipharmaceutics International Inc. , a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, reports, as required by TSX rules, that the six nominees, each of whom was an incumbent director of the Company, identified in the Management Information Circular dated November 9, 2020 were elected as directors of the Company at the annual meeting of shareholders of the Company held today . The voting results, as set out in the scrutineer’s report for the Meeting, were as follows: Name of Nominee Votes For Votes Withheld Dr. Isa Odidi 1,472,586 271,188 84.4% 15.6% Dr. Amina Odidi 1,472,143 2...",
"Report on Voting Results" |
|
| 12/15/2020 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:|
Docs:
|
"PRIMARY DOCUMENT",
"Intellipharmaceutics Announces Change in Venue for The Company’s Annual General Meeting Scheduled To Be Held on December 23, 2020 TORONTO, Ontario December 15, 2020 - Intellipharmaceutics International Inc. , a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, announced today that, due to the ongoing COVID-19 pandemic, it is changing the venue for its Annual General Meeting scheduled to be held on December 23, 2020 beginning at 11.30 am. . The change in venue of the AGM is due to increased government public health restrictions on the number of persons permitted in an indoor meeting in Halton Region where the original venue is located. The new venue for the AGM is the Casabla..." |
|
| 10/15/2020 |
6-K
| Quarterly results |
| 07/15/2020 |
6-K
| Quarterly results |
| 07/02/2020 |
6-K
| Quarterly results |
| 05/29/2020 |
6-K
| Quarterly results|
Docs:
|
"PRIMARY DOCUMENT",
"Management Discussion And Analysis Of Financial Condition And Results Of Operations for the Three Months Ended February 29, 2020",
"Condensed Unaudited Interim Consolidated Financial Statements and Notes to Condensed Unaudited Interim Consolidated Financial Statements of Intellipharmaceutics International Inc. for the Three Months Ended February 29, 2020",
"Intellipharmaceutics Announces First Quarter 2020 Results Toronto, Ontario May 29, 2020 – Intellipharmaceutics International Inc. , a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three months ended February 29, 2020. All dollar amounts referenced herein are in United States dollars unless otherwise noted. ● On April 9, 2020, we announced an update on timing of the release of our first quarter financial results for the three months ended February 29, 2020. The Canadian Securities Administrators had announced temporary relief from certain regulatory filings required to be made on or before June 1, 2020 by reporting i...",
"Form 52-109F2 - Chief Executive Officer",
"Form 52-109F2 - Chief Financial Officer" |
|
| 03/30/2020 |
20-F
| Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: |
|
|
|